CCA
NUVB icon

Cygnus Capital Advisors’s Nuvation Bio NUVB Stock Holding History

Cygnus Capital Advisors’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,872
Closed -$17K – 96
2026
Q1 		$17K Hold
3,872
– – 0.01% 90
2025
Q4 		$35K Buy
+3,872
New +$24K 0.03% 70

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Cygnus Capital Advisors's NUVB Position: Q2 2026 in Review

Cygnus Capital Advisors sold out of Nuvation Bio (NUVB) in Q2 2026, closing a stake of 3,872 shares — an estimated $17K sold.

Cygnus Capital Advisors first reported a position in NUVB in Q4 2025 and held it in 2 quarters. The position peaked at $35K in Q4 2025. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Cygnus Capital Advisors reported no remaining Nuvation Bio position as of Q2 2026 after selling out during the quarter.
  • Cygnus Capital Advisors sold 3,872 Nuvation Bio shares in Q2 2026, an estimated $17K.
  • Cygnus Capital Advisors first reported a position in Nuvation Bio in Q4 2025 and held it in 2 quarters.
  • Cygnus Capital Advisors's Nuvation Bio position peaked at $35K in Q4 2025.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Cygnus Capital Advisors's 13F filing for Q2 2026, filed 3 Sep 2026.